Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now LSE - Delayed Quote • EUR Qiagen N.V. (0RLT.L) Follow Add holdings 47.25 +0.31 +(0.65%) At close: July 22 at 8:34:14 AM GMT+1 Comparisons Indicators Technicals Corporate Events Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for 0RLT.L 1D 5D 1M 3M 6M YTD 1Y 5Y All Date Range 1 min Recent News: 0RLT.L View More All News Press Releases SEC Filings QIAGEN Advances Cancer Genomic Profiling With New Products and Partnership Updates at AACR Annual Meeting 2025 Is There An Opportunity With Qiagen N.V.'s (NYSE:QGEN) 33% Undervaluation? QIAGEN Advancing Plans to Launch Three New Sample Preparation Instruments by 2026 to Improve Lab Automation QIAGEN N.V. to Release Results for Q1 2025 and Hold Webcast QIAGEN Delivers Strong Preliminary Q1 2025 Results Exceeding Outlook and Raises Full-Year 2025 Adjusted EPS Outlook Qiagen Full Year 2024 Earnings: EPS Misses Expectations QIAGEN Launches QIAprep& Plasmodium Kit to Strengthen Malaria Research and Surveillance Efforts QIAGEN Announces Form 20-F Annual Report Filing for 2024 Results Are Qiagen N.V.'s (NYSE:QGEN) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market? The past three-year earnings decline for Qiagen (NYSE:QGEN) likely explains shareholders long-term losses QIAGEN receives U.S. clearance for second QIAstat-Dx mini gastrointestinal panel, expanding U.S. syndromic testing portfolio